Core Points - The company has prepared a special report on the use of raised funds for the first half of 2025, ensuring compliance with relevant regulations and confirming the accuracy of the report [1][2][5] Fundraising Overview - The company raised a total of RMB 1,754.386 million by issuing 17.54 million shares at a price of RMB 106.19 per share, with the total expected fundraising amount being RMB 1,754.386 million [1] - As of June 30, 2025, the cumulative investment of raised funds amounted to RMB 429.0863 million, with interest income received totaling RMB 91.1389 million and bank fees paid of RMB 0.0066 million, leaving a balance of RMB 1,404.2419 million [1][2] Fund Management - The company has established a fundraising management method to regulate the storage, approval, use, management, and supervision of raised funds, ensuring investor protection [2] - A tripartite supervision agreement has been signed with various banks to manage the special account for raised funds, with a balance of RMB 659.9814 million as of June 30, 2025 [2][3] Actual Use of Funds - As of June 30, 2025, the company has not used idle raised funds to temporarily supplement working capital [3] - The company has approved the use of idle raised funds for cash management, allowing for investments in safe and liquid products up to RMB 1 billion, with a total of RMB 744.2187 million in large transferable certificates of deposit as of June 30, 2025 [3][5] Other Fund Usage - The company has initiated a share repurchase plan using part of the raised funds, with a total repurchase amount between RMB 10 million and RMB 20 million, and has repurchased 404,337 shares for a total of RMB 11.9598 million as of June 30, 2025 [5][6] - There have been no changes in the direction of the raised funds or issues in the use and disclosure of the funds as of June 30, 2025 [5][6]

Core Viewpoint - The company is committed to enhancing operational quality and investor returns through its "Quality Improvement and Efficiency Enhancement Action Plan" for 2025, focusing on core competencies in recombinant protein technology and applications [1][2]. Group 1: Business Performance - The company achieved a revenue of 72.09 million yuan in the first half of 2025, representing a year-on-year increase of 20.85%, driven by improved management, product quality, and expansion into overseas markets [2]. - The recombinant protein business saw a significant growth of 43.66% year-on-year, while the overall customer base increased by 4.2% [2][6]. - The net profit attributable to shareholders was -24.22 million yuan, primarily due to high R&D and marketing investments aimed at high-quality development and reduced government subsidies [2][6]. Group 2: R&D and Innovation - The company emphasizes self-innovation, with 23 core technologies forming 7 comprehensive technology platforms, enhancing its capabilities in product development, production, and quality control [6][7]. - The company is actively developing solutions for various drug types, including RNA vaccines and antibody drugs, and is focusing on areas like organoids and three-dimensional genomics in life sciences [7][8]. Group 3: Investor Relations and Governance - The company has repurchased 404,337 shares for a total of approximately 11.96 million yuan to enhance investor confidence and maintain long-term investment value [8][9]. - The company adheres to strict information disclosure practices, ensuring transparency and communication with investors through multiple channels [9][10]. - The governance structure is continuously optimized to ensure compliance with legal regulations and to protect shareholder rights [10][11]. Group 4: Market Expansion - The company is expanding its overseas market presence by building localized teams and participating in international exhibitions related to antibody drugs and gene therapies [4][5]. - The number of overseas customers increased significantly, reflecting the company's successful market penetration strategies [5]. Group 5: Operational Efficiency - The company is implementing cost-reduction measures and enhancing production efficiency through supply chain integration and local sourcing of raw materials [3][6]. - Quality management systems such as GMP and ISO standards are strictly followed to ensure product safety and effectiveness [3][6]. Group 6: Future Outlook - The company plans to continue evaluating the execution of its action plan while focusing on core business areas and exploring new profit growth points [11]. - The commitment to sustainable long-term returns for investors remains a priority, alongside maintaining operational excellence [11].

Group 1 - The company reported a credit impairment loss of 82.76 thousand yuan, with accounts receivable bad debt loss of 90.43 thousand yuan and other receivables bad debt recovery of 7.67 thousand yuan [2] - The company recognized an asset impairment loss of 1,812.77 thousand yuan, entirely attributed to inventory write-downs [2] - The total impact of the impairment provisions on the company's consolidated profit amounted to 1,730.01 thousand yuan [2] Group 2 - The impairment provisions were made in accordance with the accounting policies and standards to reflect the financial status and operating results as of June 30, 2025 [1] - The impairment losses were not audited by the accounting firm, and investors are advised to be cautious regarding investment risks [2]

Core Viewpoint - Suzhou Nearshore Protein Technology Co., Ltd. plans to use part of its oversubscribed funds amounting to RMB 72 million for permanent working capital, which represents 29.73% of the total oversubscribed funds, pending approval from the shareholders' meeting [1][5]. Fundraising Overview - The company raised a net amount of RMB 1,742.20 million from its initial public offering, with total oversubscribed funds amounting to RMB 242.20 million [2][4]. - The total investment amount for the fundraising projects is RMB 1,500 million, with the planned use of funds from this issuance also being RMB 1,500 million [2]. Plan for Using Oversubscribed Funds - The decision to use RMB 72 million of the oversubscribed funds for working capital is aimed at meeting the company's liquidity needs and improving the efficiency of fund usage, while ensuring that the fundraising projects continue as planned [2][3]. - The company commits that the cumulative use of oversubscribed funds for permanent working capital will not exceed 30% of the total oversubscribed funds within any twelve-month period [3][4]. Review and Approval Process - The board of directors and the supervisory board have approved the proposal to use part of the oversubscribed funds for working capital, which will be submitted for further approval at the shareholders' meeting [5]. - The supervisory board believes that the decision complies with relevant regulations and does not harm the interests of the company or its shareholders, particularly minority shareholders [5].

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-033 苏州近岸蛋白质科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 拟聘任的会计师事务所名称：容诚会计师事务所（特殊普通合伙）（ 以下简称"容诚"） ? 本事项尚需提交公司股东会审议。 一、拟聘任会计师事务所的基本情况 （一）机构信息 容诚会计师事务所（特殊普通合伙）由原华普天健会计师事务所（特殊普通 合伙）更名而来，初始成立于1988年8月，2013年12月10日改制为特殊普通合伙 企业，是国内最早获准从事证券服务业务的会计师事务所之一，长期从事证券服 务业务。注册地址为北京市西城区阜成门外大街22号1幢10层1001-1至1001-26， 首席合伙人刘维。 截至2024年12月31日，容诚会计师事务所共有合伙人196人，共有注册会计 师1,549人，其中781人签署过证券服务业务审计报告。 二、项目信息 项目合伙人：李飞，2015年成为中国注册会计师，2011年开始从事上市公 司审计业务，2015年开始在容诚会计师事 ...

Core Viewpoint - The company plans to use part of the excess raised funds, amounting to 72 million RMB, to permanently supplement its working capital, which aligns with its business development needs and aims to enhance profitability while protecting shareholder interests [3][5]. Fundraising Overview - The company successfully completed its initial public offering (IPO) on September 26, 2022, raising a total of 1,742.1958 million RMB, with a total excess of 242.1958 million RMB after deducting issuance costs [1][2]. - The total investment amount for the core diagnostic raw materials and innovative diagnostic reagents industrialization project is 1,500 million RMB, which will utilize the raised funds [2]. Use of Excess Funds - The company intends to allocate 72 million RMB, which is 29.73% of the total excess funds, to permanently supplement working capital, ensuring that the funding needs for investment projects are met [3][4]. - The cumulative use of excess funds for working capital will not exceed 30% of the total excess funds within the last 12 months, complying with regulatory requirements [4]. Impact on Daily Operations and Commitments - The company commits that the use of excess funds will not affect the funding needs of investment projects and will refrain from high-risk investments or providing financial assistance to entities outside its controlling subsidiaries within the next 12 months [4][5]. - The supervisory board supports the decision, stating that it meets regulatory requirements and does not harm the interests of shareholders, particularly minority shareholders [5]. Review Process and Opinions - The proposal to use part of the excess funds was approved in nine meetings and will be submitted for shareholder approval [5]. - The sponsor institution has verified that the use of excess funds for working capital will enhance efficiency and reduce financial costs without affecting the normal progress of investment projects [5].

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-031 苏州近岸蛋白质科技股份有限公司 关于使用部分超募资金永久补充流动资金的公告 经中国证券监督管理委员会于 2022 年 7 月 25 日出具的《关于同意苏州近岸 蛋白质科技股份有限公司首次公开发行股票注册的批复》（证监许可[2022]1626 号）批准，公司首次公开发行人民币普通股（A 股）股票（以下简称"本次发行"） 17,543,860 股，每股发行价格为人民币 106.19 元，募集资金总额为人民币 186,298.25 万元；扣除发行费用后实际的募集资金净额为人民币 174,219.58 万 元。上述募集资金已于 2022 年 9 月 26 日全部到位，容诚会计师事务所（特殊普 通合伙）对公司本次发行的募集资金到位情况进行了审验，并于 2022 年 9 月 26 日出具了《验资报告》（容诚验字[2022]200Z0058 号）。为规范募集资金的使 用与管理，提高募集资金使用效益，保护投资者的合法权益，根据《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》及有关法律法规的规定， 公司已与民生证券和存放募集资金的商业银 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-030 苏州近岸蛋白质科技股份有限公司 关于2025年半年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、计提资产减值准备情况的概述 根据《企业会计准则》和苏州近岸蛋白质科技股份有限公司（以下简称"公 司"）会计政策的相关规定，为客观、公允地反映公司截至 2025 年 6 月 30 日的 财务状况和 2025 年半年度的经营成果，公司及下属子公司对截至 2025 年 6 月 30 日公司资产进行了减值测试，公司 2025 年上半年计提各项资产减值准备合计 1,730.01 万元。具体情况如下： （二）资产减值损失 公司在资产负债表日，根据存货会计政策，对存货按照成本与可变现净值孰 1 低计量，对成本高于可变现净值的，计提存货跌价准备，计入当期损益。经测试， 公司 2025 年上半年应计提存货跌价损失 1,812.77 万元。 三、计提资产减值准备对公司的影响 2025 年上半年，公司合并报表口径共计提资产减值准备 1,730.01 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-033 苏州近岸蛋白质科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：容诚会计师事务所（特殊普通合伙）（ 以下简称"容诚"） 本事项尚需提交公司股东会审议。 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 容诚会计师事务所（特殊普通合伙）由原华普天健会计师事务所（特殊普通 合伙）更名而来，初始成立于1988年8月，2013年12月10日改制为特殊普通合伙 企业，是国内最早获准从事证券服务业务的会计师事务所之一，长期从事证券服 务业务。注册地址为北京市西城区阜成门外大街22号1幢10层1001-1至1001-26， 首席合伙人刘维。 2、人员信息 截至2024年12月31日，容诚会计师事务所共有合伙人196人，共有注册会计 师1,549人，其中781人签署过证券服务业务审计报告。 3、业务规模 容诚会计师事务所经审计的2024年度收入总额为251,025.80 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-032 苏州近岸蛋白质科技股份有限公司 2025 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关法律法规的规 定及要求，苏州近岸蛋白质科技股份有限公司（以下简称"公司"）编制了 2025 年半 年度募集资金存放与实际使用情况的专项报告，具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会《关于同意苏州近岸蛋白质科技股份有限公司首次公开 发行股票注册的批复》证监许可[2022]1626 号文件核准，本公司向社会公开发行人民币 普通股（A 股）1,754.3860 万股，每股发行价为 106.19 元，应募集资金总额为人民币 186,298.25 万元，根据有关规定扣除发行费用 12,078.67 万元后，实际募集资金金额为 17 ...